Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fabre

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
BMC Cancer|April 1, 2014
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancerDelphine Lerouge, Alain Rivière, Eric Dansin, et al.
Journal of the American College of Cardiology|January 13, 2018
Selective EGF-Receptor Inhibition in CD4<sup>+</sup> T Cells Induces Anergy and Limits AtherosclerosisLynda Zeboudj, Mikael Maître, Lea Guyonnet, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2015
The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer DonorsClaire Chevaleyre, Nadine Benhamouda, Emmanuel Favry, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 4, 2026
Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studiesMarie Pautas, Pascaline Boudou-Rouquette, Anne Jouinot, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy responseYann Godet, Elizabeth Fabre, Magalie Dosset, et al.
British Journal of Cancer|July 31, 2019
Distinct prognostic value of circulating anti-telomerase CD4<sup>+</sup> Th1 immunity and exhausted PD-1<sup>+</sup>/TIM-3<sup>+</sup> T cells in lung cancerCaroline Laheurte, Magalie Dosset, Dewi Vernerey, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 28, 2024
Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessmentMariana Mirabel, Assié Eslami, Constance Thibault, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
Cancers|February 23, 2020
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyManuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
BMC Cancer|April 1, 2014
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancerDelphine Lerouge, Alain Rivière, Eric Dansin, et al.
Journal of the American College of Cardiology|January 13, 2018
Selective EGF-Receptor Inhibition in CD4<sup>+</sup> T Cells Induces Anergy and Limits AtherosclerosisLynda Zeboudj, Mikael Maître, Lea Guyonnet, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2015
The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer DonorsClaire Chevaleyre, Nadine Benhamouda, Emmanuel Favry, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 4, 2026
Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studiesMarie Pautas, Pascaline Boudou-Rouquette, Anne Jouinot, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy responseYann Godet, Elizabeth Fabre, Magalie Dosset, et al.
British Journal of Cancer|July 31, 2019
Distinct prognostic value of circulating anti-telomerase CD4<sup>+</sup> Th1 immunity and exhausted PD-1<sup>+</sup>/TIM-3<sup>+</sup> T cells in lung cancerCaroline Laheurte, Magalie Dosset, Dewi Vernerey, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 28, 2024
Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessmentMariana Mirabel, Assié Eslami, Constance Thibault, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
Cancers|February 23, 2020
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyManuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, et al.
Pageof 8